Categories: NewsPharmaceutical

Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022

STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second quarter 2022 financial results after the market closes on Thursday, August 4, 2022. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Conference Call Information 

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2022 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Contact:
Alex Dasalla
Head of Investor Relations
adasalla@collegiumpharma.com

Staff

Recent Posts

MEDITECH Announces the Passing of Founder and Chairman A. Neil Pappalardo

Reflections on his 56-year legacy as a tech pioneer and founder of the EHR industryCANTON,…

1 hour ago

eClinicalWorks and Sunoh.ai Assist Healthy Horizons Clinic Save Over Two Hours Daily on Clinical Documentation

Multispecialty practice transforms patient care, improves operational efficiency, and increases patient engagement with AI medical…

1 hour ago

TRNR Publishes Comprehensive Sportstech Documentation for Shareholders

Timeline and Source Materials Now Available at interactivestrength.com/sportstech AUSTIN, TEXAS / ACCESS Newswire / January…

1 hour ago

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

4 hours ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…

4 hours ago

Illumina completes acquisition of SomaLogic

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…

4 hours ago